-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GSK-5462688 in Alpha-1 Antitrypsin Deficiency (A1AD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GSK-5462688 in Alpha-1 Antitrypsin Deficiency (A1AD) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GSK-5462688 in Alpha-1 Antitrypsin Deficiency (A1AD) Drug Details: GSK-5462688 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Prednisone in Asthma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Prednisone in Asthma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Prednisone in Asthma Drug Details: Prednisone (ORB-101) is under development for the treatment...
-
Thematic Analysis
Agriculture M&A Deals 2023 – Top Themes – Thematic Intelligence
This report analyzes the disruptive themes that have driven M&A activity in 2023 in the Agriculture Sector.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – WVE-006 in Alpha-1 Antitrypsin Deficiency (A1AD)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. WVE-006 in Alpha-1 Antitrypsin Deficiency (A1AD) Drug Details: WVE-006 are under development for the treatment...
-
Product Insights
NewBronchiolitis – Drugs In Development, 2024
Empower your strategies with our Bronchiolitis – Drugs In Development, 2024 report and make more profitable business decisions. Bronchiolitis is inflammation of the small airways in the lungs. It is the most common lower respiratory tract infection in pediatric patients between 1 month and 2 years of age. It is usually caused by the respiratory syncytial virus (RSV) and is characterized by inflammation, edema, and necrosis of the bronchiole's epithelium. It is transmitted by air droplets. symptoms of bronchiolitis include fever,...
-
Product Insights
NewNephrotic Syndrome – Drugs In Development, 2024
Empower your strategies with our Nephrotic Syndrome – Drugs In Development, 2024 report and make more profitable business decisions. Nephrotic syndrome is a kidney disorder that causes the body to excrete too much protein in the urine. Nephrotic syndrome is usually caused by damage to the clusters of small blood vessels in kidneys that filter waste and excess water from blood. Symptoms include severe swelling (edema), foamy urine, and weight gain due to excess fluid retention. Risk factors include diabetes, lupus,...
-
Product Insights
NewNasopharyngitis (Common Cold) – Drugs In Development, 2024
Empower your strategies with our Nasopharyngitis (Common Cold) – Drugs In Development, 2024 report and make more profitable business decisions. Nasopharyngitis, also known as the common cold, is an infectious inflammatory condition that affects the throat and nasal passages. The virus can spread through droplets in the air when someone who is sick coughs, sneezes, or talks. Symptoms include sore throat, runny nose, sneezing, fatigue, headache, and loss of appetite. Risk factors include age and weakened immune system. Treatment includes pain...
-
Product Insights
NewAcute Sensorineural Hearing Loss – Drugs In Development, 2024
Empower your strategies with our Acute Sensorineural Hearing Loss – Drugs In Development, 2024 report and make more profitable business decisions. Acute sensorineural hearing loss refers to a sudden and rapid reduction in hearing sensitivity, often exceeding 30 decibels, within a short period. Typically, this condition affects only one ear, accompanied by symptoms like dizziness and the presence of ringing in the ears, known as tinnitus (observed in 40% of cases). Various factors contribute to this condition, ranging from infections and...
-
Product Insights
NewBronchitis – Drugs In Development, 2024
Empower your strategies with our Bronchitis – Drugs In Development, 2024 report and make more profitable business decisions. Bronchitis is an inflammation of the lining of bronchial tubes, which carry air to and from lungs. Symptoms include cough that produces mucus (sputum), which may be blood streaked; shortness of breath aggravated by exertion or mild activity; frequent respiratory infections worsen symptoms; wheezing, fatigue, and headaches. Risk factors include smoking, older age and gastric reflux. The Bronchitis drugs in development market research...
-
Product Insights
NewEosinophilic Esophagitis – Drugs In Development, 2024
Empower your strategies with our Eosinophilic Esophagitis – Drugs In Development, 2024 report and make more profitable business decisions. Eosinophilic esophagitis is disease characterized by the presence of a large number of a special type of white blood cell, the eosinophil, that can cause inflammation in the esophagus. Symptoms include poor weight gain, abdominal pain, nausea, and vomiting; coughing; heartburn; and chest pain. Risk factors include weakened immune system, chemotherapy, aspirin and anti-inflammatory medications, chronic vomiting, obesity, and alcohol or cigarette...